Repare Therapeutics Shares Business, Clinical Update & 2024 Financial Results Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, has released its financial results for the fourth quarter and full year ending December 31, 2024.…
SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings SmithRx, a transparent and fully pass-through modern pharmacy benefits manager (PBM), has announced a significant expansion of its Connect 360 Autoimmune Program. This initiative includes the introduction of Stelara biosimilars, new low-cost Humira…
Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio Demetra Holding, a pioneering and independent international medical device company specializing in anti-infective cements, spacers, and biomaterials for orthopedic applications, has announced its strategic acquisition of a 51% stake…
Identiv and Novanta Forge Strategic Partnership to Accelerate Adoption of RFID Solutions in Healthcare OEMs Novanta Inc., a leading global technology supplier serving the medical device and life sciences markets, has announced a strategic business development and marketing partnership with…
IPA and RIBOPRO Forge Strategic Partnership to Revolutionize mRNA-Based Antibody Discovery and Expand Immunotherapy Horizons ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, has announced a landmark strategic collaboration with…
Aurinia Pharmaceuticals Announces Strong Financial Performance for Q4 and Full Year 2024, Provides Corporate Updates Fourth Quarter and Full-Year 2024 Financial Performance Highlights Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a leading biopharmaceutical company focused on advancing therapies for autoimmune diseases, announced…
LEO Pharma’s Anzupgo® Meets Phase 3 Endpoint in China for Chronic Hand Eczema LEO Pharma A/S, a global leader in medical dermatology, has announced positive results from the double-blind treatment period of the DELTA China trial. This phase 3 clinical…
Latus Bio Presents Preclinical Data Supporting Its Huntington’s Disease Gene Therapy Program Latus Bio, Inc. (Latus), a biotechnology company pioneering advancements in adeno-associated virus (AAV) gene therapy, is pleased to announce the presentation of new preclinical data supporting its investigational…
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance GeneDx Holdings Corp. (Nasdaq: WGS), a leader in leveraging genomic insights to drive improved health outcomes, has announced its financial results for the fourth quarter and…
Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug Abcuro, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat autoimmune diseases and cancer by precisely modulating cytotoxic T cells, has successfully closed a $200 million…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has successfully closed its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT), which was initially announced on November 26, 2024. The closing of this highly anticipated transaction was contingent upon the expiration or…
Aurion Biotech, Inc. (Aurion), a company dedicated to restoring vision for millions through transformative regenerative therapies, has announced the appointment of Donald Munoz as Chief Financial Officer (CFO). Munoz will report directly to Greg Kunst, Chief Executive Officer (CEO), and…